Clinical intelligence that connects what specialists miss.
Ailva, a clinical intelligence platform for physicians, is built by Scrivly, Inc. in Austin, Texas.
The story
It takes an average of 17 years for a landmark clinical study to translate into standard practice. In that time, 1.5 million new biomedical articles are published every year, each one potentially containing the evidence a physician needs for the patient sitting in front of them. The gap between what medicine knows and what physicians can access at the point of care is not a failure of effort — it is a structural problem that grows wider every year.
The tools available today either retrieve and summarize — search engines with a summarization layer — or provide static expert-authored content with a search interface layered on top. Neither reasons across organ systems. Neither surfaces the connections that a brilliant integrative physician with perfect literature recall would see: the cardio-renal interaction that changes a drug choice, the drug-nutrient depletion that explains treatment resistance, the subgroup analysis from a nephrology trial that matters to a cardiologist.
Ailva was built to close that gap. Not a search engine. Not a chatbot. A clinical intelligence platform that understands how biological systems interconnect, and can synthesize patient-specific evidence with verified citations in seconds. Every claim is cited. Every citation is verified against 5 million indexed peer-reviewed papers. Every response is built for the physician who needs to act now and needs to trust what they are reading. See how Ailva works in practice.
Team
Sam Anderson
CEO & Co-Founder
Building clinical intelligence that gives every physician the reasoning power of a world-class integrative specialist. Previously worked across full-stack engineering and health technology. Based in Austin, TX.
What is the bench-to-bedside gap?
The bench-to-bedside gap is the delay between when clinical evidence is published and when it reaches routine medical practice. A landmark 2001 study by Balas and Boren estimated this gap at 17 years on average. During that time, patients who could benefit from published evidence are not receiving it. Ailva was built to compress this gap by giving physicians immediate access to synthesized, patient-specific evidence from over 5 million indexed peer-reviewed papers at the point of care.
What problem does Ailva solve?
Ailva solves the evidence-access problem in clinical medicine. Over 1.5 million biomedical articles are published every year, and no physician can track all the evidence relevant to their patients. Existing tools either retrieve from a single specialty or provide static expert-authored summaries. Ailva synthesizes evidence across 46 specialties, surfaces cross-system connections, and delivers patient-specific answers with verified citations in seconds.
Who built Ailva?
Ailva is built by Scrivly, Inc., based in Austin, Texas. It was founded by Sam Anderson, CEO and Co-Founder, to close the gap between what medicine knows and what physicians can access at the point of care. The platform is free for all NPI-verified US healthcare professionals.